Becker's Healthcare January 31, 2024
As part of its new cell and gene therapy access tool, HHS’ first focus is improving access to sickle cell disease therapies, which can cost millions of dollars for a one-time dose.
Sickle cell disease is an extremely painful condition that affects more than 100,000 Americans and disproportionately affects Black patients, HHS said in a Jan. 31 news release. Historically, there were limited therapies available for sickle cell patients, but recent approvals have broadened their options.
The list prices for some of these new drugs, such as Casgevy...
Today's Sponsors
Today's Sponsor